Get him back in to assess the response to treatment

Without proper dose titration, your adult male patients may not see the treatment results they need or were expecting. That’s why it’s so important to monitor your patients and titrate their dosage based on the normal testosterone level range.1

Monitor pre-dose morning serum total testosterone (TT) concentration1:

  • 14 and 28 days after starting treatment
  • Following dose adjustment
  • Periodically during treatment and titrate dose based on patient’s response to therapy

Titration guidelines for AndroGel 1.62%1

Pre-dose morning serum total testosterone concentration

Dose titration

>750 ng/dL

Decrease daily dose by 20.25 mg

350-750 ng/dL

Continue on current dose

<350 ng/dL

Increase daily dose by 20.25 mg

Find Clinical Data and titration guidelines for AndroGel 1.62%

Clinical trial titration rates3

In the 182-day clinical study, 74% of patients had their dose titrated based on treatment response. Patients’ total serum testosterone levels were assessed on Days 14, 28, and 42, and dosing adjustments were made when indicated.

Additional considerations for titration1

Increases in hematocrit:

  • Monitor hematocrit prior to and periodically during treatment. Monitor hemoglobin periodically. Increases in hematocrit, reflective of increases in red blood cell mass, may require lowering or discontinuation of testosterone replacement therapy. An increase in red blood cell mass may increase the risk of thromboembolic events

Changes in serum lipid profile:

  • Monitor lipid concentrations periodically. Changes in serum lipid profile may require dose adjustment or discontinuation of testosterone therapy

Safety Considerations1

  • Avoid unintentional exposure of women or children to AndroGel 1.62%. Secondary exposure to testosterone can produce signs of virilization. Exposure of a pregnant woman to AndroGel may result in potential hazard to the fetus. AndroGel 1.62% should be promptly discontinued until the cause of virilization is identified.